INDP
Indaptus Therapeutics, Inc.2.2100
-0.1000-4.33%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
3.87MP/E (TTM)
-Basic EPS (TTM)
-29.03Dividend Yield
0%Recent Filings
10-Q
8-K
8-K
Decoy20 partial response in trial
Indaptus Therapeutics announced on September 4, 2025, that its Decoy20 monotherapy induced a partial response in a urothelial cancer patient with liver metastases, reducing tumor size over four months before progression. The company completed the monotherapy arm of the INDP-D101 trial and dosed seven patients in the initial combination cohort with tislelizumab, showing safety consistent with each agent alone; one of three evaluable patients had stable disease. It raised $5.7 million in gross proceeds from convertible notes in July 2025, converted to stock and warrants, bolstering its balance sheet amid ongoing clinical execution. Yet risks like funding needs loom large.
8-K
First combo trial patient dosed
Indaptus Therapeutics dosed its first patient in a Phase 1b/2 trial combining Decoy20 with PD-1 inhibitor tislelizumab, building on preclinical synergy for tumor regression. R&D expenses climbed to $2.2 million in Q2 2025 from $1.7 million last year, driven by the ongoing Phase 1 study, while a $5.7 million note financing—converted to equity in July—bolsters the balance sheet. Cash stands at $6.2 million, funding operations into Q4 2025. Initial trial data arrives later this year.
10-Q
Q2 FY2025 results
Indaptus Therapeutics posted a Q2 net loss of $5.2 million, up 30% year-over-year from $4.0 million, driven by $2.2 million in research and development expenses that climbed 26% on higher clinical trial costs for its Phase 1 Decoy20 study, while general and administrative costs dipped 4% to $2.3 million amid lower stock-based compensation but offset by $0.8 million in transaction fees from a June convertible notes offering. The net loss exceeded the operating loss by $0.8 million due to a fair-value increase on those notes, now converted post-quarter into 501,566 shares at $8.30 per share plus warrants for 1.4 million shares. Cash stood at $6.2 million after $9.1 million in operating burn, bolstered by $9.4 million from equity sales and notes; free cash flow not disclosed in the 10-Q. The company eyes Q4 2025 runway but flags going-concern doubts without fresh capital. Clinical progress includes dosing in a Decoy20-Tislelizumab combo trial, yet trial delays could stall momentum.
ADPT
Adaptive Biotechnologies Corpor
15.93+0.24
BVAXD
BioVaxys Technology Corp.
0.15-0.03
HEPA
Hepion Pharmaceuticals, Inc.
0.07-0.01
INAB
IN8bio, Inc.
1.50-0.10
INTS
Intensity Therapeutics, Inc.
0.44+0.02
NUVB
Nuvation Bio Inc.
8.66+0.15
NVCT
Nuvectis Pharma, Inc.
7.69+0.04
TIL
Instil Bio, Inc.
11.25+0.13
VINC
Vincerx Pharma, Inc.
0.01+0.00
VIR
Vir Biotechnology, Inc.
6.48-0.24